Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SCIO-469

Known as: SCIO 469 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome 
  • table 1
  • table 2
Is this relevant?
2012
2012
SCIO-469 is a selective p38α mitogen-activated protein kinase (MAPK) inhibitor for preclinical models of acute pain. This… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Objective. To evaluate the efficacy, safety, and tolerability of oral SCIO-469, a p38 MAPK inhibitor that blocks tumor necrosis… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
The myelodysplastic syndromes (MDSs) are collections of heterogeneous hematologic diseases characterized by refractory cytopenias… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Arsenic trioxide (As(2)O(3)) induces differentiation and apoptosis of leukemic cells in vitro and in vivo, but the precise… Expand
Is this relevant?
2006
2006
Background: p38a mitogen-activated protein kinase (MAPK) mediates production of proinflammatory cytokines and other factors… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
The multiple myeloma (MM) bone marrow (BM) microenvironment plays a critical role in supporting tumor growth and survival as well… Expand
Is this relevant?
2006
2006
Inhibition of p38 kinase blocks the production of tumor-promoting factors in the multiple myeloma (MM) bone marrow… Expand
Is this relevant?
2004
2004
This double-blind, randomized study compared the analgesic efficacy, safety and tolerability of pre- and post-operatively… Expand
Is this relevant?
Review
2004
Review
2004
SCIO-469 is a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor under development by Scios Inc as a potential… Expand
Is this relevant?